Biogen up after FDA grants 'breakthrough' tag for neuromuscular disorder drug
04/06/2026 13:39
BUZZ-Biogen up after FDA grants 'breakthrough' tag for neuromuscular disorder drug ** Shares of Biogen BIIB.O rise 1.1% to $198.02 premarket
** The drugmaker says the U.S. Food and Drug Administration granted breakthrough therapy designation to its experimental drug salanersen for spinal muscular atrophy (SMA)
** The breakthrough therapy tag is meant to speed up development and review of drugs to treat serious conditions or those with unmet medical needs
** SMA is a rare genetic disease that causes severe muscle weakness and can be fatal
** The tag was based on early stage data showing that drug may offer substantial improvement over currently available therapies - BIIB
** Up to last close, stock up 11.4% YTD
(Reporting by Siddhi Mahatole)
Recent news on Biogen
See all newsUS RESEARCH ROUNDUP-Autodesk, Metlife, Rollins
Brief: Biogen Says DZP Plus Soc Meets Primary Endpoint Of BICLA Response At Week 48
Brief: Biogen Provides Update On Private Payer Coverage For Zurzuvae™ (Zuranolone)
US RESEARCH ROUNDUP-Eli Lilly, General Dynamics, S&P Global
US RESEARCH ROUNDUP-Baker Hughes, Brinker International, GE Vernova